

# Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis and Reflex to Titer and Neuronal Immunoblot

Patient: [REDACTED]  
 DOB: [REDACTED] Age: 77 Sex: M  
 Patient Identifiers: [REDACTED]  
 Visit Number (FIN): [REDACTED]

Client: [REDACTED]  
 Physician: [REDACTED]

ARUP Test Code: 2007967  
 Collection Date: 01/11/2022  
 Received in lab: 01/13/2022  
 Completion Date: 01/16/2022

## MAG Antibody, IgM Elisa

<1000 TU (Ref Interval: 0-999)

INTERPRETIVE INFORMATION: MAG Antibody, IgM ELISA

An elevated IgM antibody concentration greater than 999 TU against myelin-associated glycoprotein (MAG) suggests active demyelination in peripheral neuropathy. A normal concentration (less than 999 TU) generally rules out an anti-MAG antibody-associated peripheral neuropathy.

TU=Titer Units

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

## SGPG Antibody, IgM

0.01 IV (Ref Interval: 0.00-0.99)

INTERPRETIVE INFORMATION: SGPG Antibody, IgM

The majority of sulfate-3-glucuronyl paragloboside (SGPG) IgM-positive sera will show reactivity against MAG. Patients who are SGPG IgM positive and MAG IgM negative may have multi-focal motor neuropathy with conduction block.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

## Purkinje Cell/Neuronal Nuclear IgG Scrn

None Detected (Ref Interval: None Detected)

ANNA-1, ANNA-2, PCCA-1 or PCCA-Tr(DNER) antibodies not detected. No further testing will be performed.

INTERPRETIVE INFORMATION: Purkinje Cell/Neuronal Nuclear IgG Scrn

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

## Asialo-GM1 Antibodies, IgG/IgM

8 IV (Ref Interval: 0-50)

## GM1 Antibodies, IgG/IgM

10 IV (Ref Interval: 0-50)

## GD1a Antibodies, IgG/IgM

5 IV (Ref Interval: 0-50)

## GD1b Antibodies, IgG/IgM

6 IV (Ref Interval: 0-50)

## GQ1b Antibodies, IgG/IgM

5 IV (Ref Interval: 0-50)

INTERPRETIVE INFORMATION: Ganglioside (Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b) Antibodies, IgG/IgM



Patient: [REDACTED]  
 ARUP Accession: 22-011-120123

# Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis and Reflex to Titer and Neuronal Immunoblot

Patient: [REDACTED] | Date of Birth: [REDACTED] | Sex: M | Physician: [REDACTED]  
Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

29 IV or less: Negative  
30-50 IV: Equivocal  
51-100 IV: Positive  
101 IV or greater: Strong Positive

Ganglioside antibodies are associated with diverse peripheral neuropathies. Elevated antibody levels to ganglioside-monosialic acid (GM1), and the neutral glycolipid, asialo GM1 are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy. Anti-GM1 may occur as IgM (polyclonal or monoclonal) or IgG antibodies. These antibodies may also be found in patients with diverse connective tissue diseases as well as normal individuals. GD1a antibodies are associated with different variants of Guillain-Barre syndrome (GBS) particularly acute motor axonal neuropathy while GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. Anti-GQ1b antibodies are seen in more than 80 percent of patients with Miller-Fisher syndrome and may be elevated in GBS patients with ophthalmoplegia. The role of isolated anti-GM2 antibodies is unknown. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**Immunoglobulin G** **1670 mg/dL** **H** (Ref Interval: 768-1632)  
REFERENCE INTERVAL: Immunoglobulin G

Access complete set of age- and/or gender-specific reference intervals for this test in the ARUP Laboratory Test Directory (aruplab.com).

**Immunoglobulin A** **36 mg/dL** **L** (Ref Interval: 68-408)  
REFERENCE INTERVAL: Immunoglobulin A

Access complete set of age- and/or gender-specific reference intervals for this test in the ARUP Laboratory Test Directory (aruplab.com).

**Immunoglobulin M** **15 mg/dL** **L** (Ref Interval: 35-263)  
REFERENCE INTERVAL: Immunoglobulin M

Access complete set of age- and/or gender-specific reference intervals for this test in the ARUP Laboratory Test Directory (aruplab.com).

**Total Protein, Serum** **7.2 g/dL** (Ref Interval: 6.3-8.2)

**Albumin** **3.90 g/dL** (Ref Interval: 3.75-5.01)

**Alpha 1 Globulin** **0.29 g/dL** (Ref Interval: 0.19-0.46)

**Alpha 2 Globulin** **0.91 g/dL** (Ref Interval: 0.48-1.05)

**Beta Globulin** **0.59 g/dL** (Ref Interval: 0.48-1.10)

**Gamma** **1.50 g/dL** (Ref Interval: 0.62-1.51)

**Immunofixation** IFE Done



Patient: [REDACTED]  
ARUP Accession: 22-011-120123

# Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis and Reflex to Titer and Neuronal Immunoblot

Patient: [REDACTED] | Date of Birth: [REDACTED] | Sex: M | Physician: [REDACTED]  
Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

## SPEP/IFE Interpretation

See Note

M-spike in the gamma region. The monoclonal protein peak accounts for 1.20 g/dL of the total 1.50 g/dL of protein in the gamma region. Suspicious broadening of the complement component in the beta region. IFE gel pattern shows an IgG type lambda monoclonal protein.

Only the Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis results are included in this enhanced report. If the reflex test is added, those results can be accessed via a patient report or electronic medical record system after reflex testing is completed. Reflex testing occurs when neuronal nuclear IgG (purkinje cell) IFA results are positive. A titer is added, and if that titer is positive, neuronal nuclear IgG (Hu, Ri, and Yo) testing is added.

**Note: Electrophoresis image and Immunofixation (IFE) Gel image, as applicable, continue on following page.**




Patient: [REDACTED]  
ARUP Accession: 22-011-120123

# Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis and Reflex to Titer and Neuronal Immunoblot

Patient: [REDACTED] | Date of Birth [REDACTED] | Sex: M | Physician: [REDACTED]  
Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

**Electrophoresis Image**



**Immunofixation (IFE) Gel Image**



Patient: [REDACTED]  
ARUP Accession: 22-011-120123